{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056260","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.175991+00:00","generated_at":"2026-06-02T07:13:40.022238+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexeo Q1 net loss $21.7M; cash $195.1M after $95M PIPE; pipeline milestones on track","bullets":["Q1 2024 net loss $21.7M ($0.77/share) vs $18.7M ($11.58/share) in Q1 2023.","Cash and equivalents $195.1M at March 31, 2024, after $95M PIPE; runway into 2027.","LX2006 (FA cardiomyopathy) granted FDA Fast Track; interim readout mid-2024.","LX2020 (PKP2-ACM) Phase 1/2 trial recruiting; Cohort 1 data update expected 2H 2024.","LX1001 (APOE4 Alzheimer's) all-cohort interim data expected 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056260","json":"https://secwatch.observer/filing/0000950170-24-056260.json","markdown":"https://secwatch.observer/filing/0000950170-24-056260.md","text":"https://secwatch.observer/filing/0000950170-24-056260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024056260/0000950170-24-056260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024056260/lxeo-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:13:40.022238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33508cbc0e6ad7bcea5948a1c4bb68365672a5d6","claim":"Lexeo Therapeutics, Inc. reported first quarter 2024 results: net income $21.7 million or $0.77 per share (basic and diluted), EPS $0.77 per share (basic and diluted).","evidence_excerpt":"Net loss was $21.7 million or $0.77 per share (basic and diluted) for the three months ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024056260/0000950170-24-056260-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Net income","value":"$21.7 million or $0.77 per share (basic and diluted)"},{"label":"EPS","value":"$0.77 per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}